Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study
Open Access
Abstract
Introduction Psoriasis is a chronic inflammatory skin disease. Adalimumab is an effective but previously expensive biological treatment for psoriasis. The introduction of biosimilars following the patent expiry of the originator adalimumab Humira has reduced the unit cost of treatment. However, the long-term effectiveness and safety of adalimumab biosimilars for treating psoriasis in real-world settings are uncertain and may be a barrier to widespread usage. Methods and analysis This study aims to compare the drug survival and safety of adalimumab biosimilars to adalimumab originator for the treatment of psoriasis. We will use both routinely collected healthcare databases and dedicated pharmacovigilance registries from the PsoNet initiative, including data from the UK, France and Spain. We will conduct a cohort study using a prevalent new user design. We will match patients on previous adalimumab exposure time to create two equal-sized cohorts of biosimilar and originator users. The coprimary outcomes are drug survival, defined by the time from cohort entry to discontinuation of the drug of interest; and risk of serious adverse events, defined by adverse events leading to hospitalisation or death. Cox proportional hazards models will be fitted to calculate HRs as the effect estimate for the outcomes. Ethics and dissemination The participating registries agree with the Declaration of Helsinki and received approval from local ethics committees. The results of the study will be published in scientific journals and presented at international dermatology conferences by the end of 2023.Keywords
Funding Information
- Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene
- Amgen, Arena, Astellas
- UCB
- Pfizer
- Novartis
- Leo
- Janssen, Lilly
- Celgene
- GSK, Janssen, Lilly, Leo, Novartis, Pfizer, Sanofi, Sun Pharma, UCB
- The BAD
- British Association of Dermatologists
- University of Manchester
- The British Association of Dermatologists
- Amgen
- NIHR Manchester Biomedical Research Centre (NIHR203308)
- Psoriasis Association
- BAD
- UCB Pharma
- Sandoz
- Amgen, Celgene, Janssen, LEO Pharma, Lilly, Novartis, Samsung
- AbbVie
This publication has 23 references indexed in Scilit:
- Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of IrelandBritish Journal of Dermatology, 2018
- Value of a national administrative database to guide public decisions: From the système national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in FranceRevue D'Épidémiologie Et de Santé Publique, 2017
- The Language of Biosimilars: Clarification, Definitions, and Regulatory AspectsDrugs, 2017
- Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti–tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registriesJournal of the American Academy of Dermatology, 2017
- Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scoresPharmacoepidemiology and Drug Safety, 2016
- Demographics and disease characteristics of patients with psoriasis enrolled in theBritishAssociation ofDermatologistsBiologicInterventionsRegisterBritish Journal of Dermatology, 2015
- Biosimilars in psoriasis: What can we expect?JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2014
- Multiple imputation for missing data in epidemiological and clinical research: potential and pitfallsBMJ, 2009
- Medication Compliance and Persistence: Terminology and DefinitionsValue in Health, 2008
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007